2008 Annual Meeting | Clinical Approach to Muscle Disease

Date Monday 04/14/08

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Matthew P. Wicklund, MD, FAAN

Topic(s)

Learning Objectives Participants should become familiar with the evaluation and treatment of acquired and genetic muscle disorders, including basic, unusual, and novel diseases; broaden their differential diagnoses; and better understand diagnostic and therapeutic advances.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
09:00 AM - 09:45 AM		Inflammatory Myopathies Anthony A. Amato, MD, FAAN
09:45 AM - 10:30 AM		Limb-Girdle Muscular Dystrophies Matthew P. Wicklund, MD, FAAN
10:30 AM - 10:50 AM		Break
10:30 AM - 11:35 PM		Myasthenia Gravis and Myasthenic Syndromes Janice M. Massey, MD, FAAN
11:35 AM - 12:20 PM		Pattern Approach to Diagnosis of Myopathies John H. Sladky, MD, FAAN
12:20 PM - 12:45 PM		Unusual Case Presentations

Faculty Disclosures
Janice M. Massey, MD, FAAN	Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance .
Anthony A. Amato, MD, FAAN	Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abscuro. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Caballeta. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Amato has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viridian Therapeutics. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medpace. Dr. Amato has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for legal firms. The institution of Dr. Amato has received research support from NIH. Dr. Amato has received publishing royalties from a publication relating to health care.
Matthew P. Wicklund, MD, FAAN	Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Dr. Wicklund has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. The institution of Dr. Wicklund has received research support from Orphazyme. The institution of Dr. Wicklund has received research support from Muscular Dystrophy Association. The institution of Dr. Wicklund has received research support from Coalition to Cure Calpain 3. The institution of Dr. Wicklund has received research support from Sarepta Therapeutics. The institution of Dr. Wicklund has received research support from ML Bio. The institution of Dr. Wicklund has received research support from Alexion. The institution of Dr. Wicklund has received research support from Acceleron. The institution of Dr. Wicklund has received research support from Edgewise. The institution of Dr. Wicklund has received research support from Fulcrum. The institution of Dr. Wicklund has received research support from Roche-Genentech. The institution of Dr. Wicklund has received research support from Avidity. Dr. Wicklund has received research support from Harmony Bioscience.
John H. Sladky, MD, FAAN	Dr. Sladky has nothing to disclose.

��ɫ��

��ɫ��